Kadmon (NYSE:KDMN) Rating Reiterated by HC Wainwright

HC Wainwright restated their buy rating on shares of Kadmon (NYSE:KDMN) in a report published on Sunday morning, AnalystRatings.com reports. The brokerage currently has a $25.00 price target on the stock.

A number of other analysts also recently commented on KDMN. Oppenheimer restated a buy rating and set a $8.00 price objective on shares of Kadmon in a report on Thursday, May 7th. ValuEngine upgraded Kadmon from a hold rating to a buy rating in a report on Thursday, April 2nd. Raymond James started coverage on Kadmon in a report on Tuesday, May 19th. They set an outperform rating and a $7.00 price objective for the company. Finally, Zacks Investment Research upgraded Kadmon from a hold rating to a buy rating and set a $5.25 price objective for the company in a report on Thursday, June 4th. Seven equities research analysts have rated the stock with a buy rating, Kadmon presently has a consensus rating of Buy and a consensus price target of $10.88.

Shares of Kadmon stock opened at $5.17 on Friday. Kadmon has a fifty-two week low of $1.98 and a fifty-two week high of $5.50. The firm has a market cap of $812.95 million, a PE ratio of -7.39 and a beta of 1.47. The business’s fifty day moving average is $4.64 and its two-hundred day moving average is $4.43. The company has a quick ratio of 6.40, a current ratio of 6.42 and a debt-to-equity ratio of 0.20.

Kadmon (NYSE:KDMN) last released its quarterly earnings data on Thursday, May 7th. The company reported ($0.19) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.05). The firm had revenue of $6.74 million for the quarter, compared to analyst estimates of $0.38 million. Kadmon had a negative return on equity of 142.79% and a negative net margin of 813.33%. Equities research analysts anticipate that Kadmon will post -0.61 EPS for the current year.

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Aperio Group LLC increased its holdings in Kadmon by 14.8% in the 1st quarter. Aperio Group LLC now owns 18,971 shares of the company’s stock valued at $79,000 after purchasing an additional 2,446 shares in the last quarter. Principal Financial Group Inc. increased its holdings in Kadmon by 19.6% in the 1st quarter. Principal Financial Group Inc. now owns 20,207 shares of the company’s stock valued at $85,000 after purchasing an additional 3,318 shares in the last quarter. Amalgamated Bank increased its holdings in Kadmon by 16.1% in the 4th quarter. Amalgamated Bank now owns 27,270 shares of the company’s stock valued at $124,000 after purchasing an additional 3,785 shares in the last quarter. Meeder Asset Management Inc. increased its holdings in Kadmon by 49.1% in the 4th quarter. Meeder Asset Management Inc. now owns 14,843 shares of the company’s stock valued at $68,000 after purchasing an additional 4,888 shares in the last quarter. Finally, Horizon Kinetics Asset Management LLC increased its holdings in Kadmon by 6.1% in the 1st quarter. Horizon Kinetics Asset Management LLC now owns 89,733 shares of the company’s stock valued at $376,000 after purchasing an additional 5,126 shares in the last quarter. Hedge funds and other institutional investors own 85.64% of the company’s stock.

Kadmon Company Profile

Kadmon Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. The company markets and distributes products in various therapeutic areas, including ribavirin products for chronic hepatitis C virus infection; and distributes products in various therapeutic areas, including tetrabenazine for the treatment of chorea associated with Huntington's disease.

Featured Story: Investing in Blue-Chip Stocks

Analyst Recommendations for Kadmon (NYSE:KDMN)

Receive News & Ratings for Kadmon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon and related companies with MarketBeat.com's FREE daily email newsletter.